86 results
424B3
KZIA
Kazia Therapeutics Limited
1 May 24
Prospectus supplement
4:06pm
, minimizing hypoxia and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
1 May 24
Kazia Reports Successful Stage 1 Completion of the EVT801
4:01pm
and therefore decreases the potential for metastatic spread. The Phase 1 EVT801 monotherapy dose-finding trial targets patients with histologically
424B3
KZIA
Kazia Therapeutics Limited
27 Mar 24
Prospectus supplement
8:37am
Oligonucleotide) development for undruggable targets in CNS disease including technology for target discovery (SovarIN™), ASO drug discovery & optimization
6-K
EX-99.1
KZIA
Kazia Therapeutics Limited
26 Mar 24
Current report (foreign)
8:02am
for undruggable targets in CNS disease including technology for target discovery (SovarIN™), ASO drug discovery & optimization (SovarON™), and target validation
6-K
EX-99.1
twoppwlv
5 Sep 23
Current report (foreign)
7:02am
6-K
EX-99.1
s5fyu9fdw6k9cb1n4s
26 Jun 23
Kazia Corporate Update and Corporate Presentation
7:00am
6-K
EX-99.1
mzsop1h8v1b9em
1 Dec 22
Current report (foreign)
4:13pm
6-K
EX-99.1
u0xmqom9
15 Sep 22
Current report (foreign)
9:12am
6-K
EX-99.1
eez87co3i5hqm986gd
1 Sep 22
Current report (foreign)
4:07pm
6-K
7dcqcii l7zdms
5 Nov 21
Current report (foreign)
6:17am
6-K
b5w6la04vipdp29b1ukg
19 Apr 21
Current report (foreign)
6:17am
424B5
51duibk59ux4hboyb5qq
31 Mar 21
Prospectus supplement for primary offering
6:30am
6-K
xalwcwjbe
1 Mar 21
Current report (foreign)
6:06am
6-K
vds9 w2zfbu
21 Jun 18
Current report (foreign)
6:16am